Literature DB >> 17417874

The autolytic regulation of human kallikrein-related peptidase 6.

Sachiko I Blaber1, Hyesook Yoon, Isobel A Scarisbrick, Maria Aparecida Juliano, Michael Blaber.   

Abstract

Human kallikrein-related peptidase 6 (KLK6) is a member of the kallikrein family of serine-type proteases, characterized as an arginine-specific digestive-type protease capable of degrading a wide-variety of extracellular matrix proteins. KLK6 has been proposed to be a useful biomarker for breast and ovarian cancer prognosis, is abundantly expressed in the CNS and cerebrospinal fluid, and is intimately associated with regions of active inflammatory demyelination in multiple sclerosis (MS) lesions. Inhibition of KLK6 results in delayed onset and reduced severity of symptoms associated with experimental autoimmune encephalomyelitis, suggesting a key effector role for this protease in CNS inflammatory disease. KLK6 has been shown to autolytically cleave internally, leading to inactivation and suggesting a negative feedback inhibition control mechanism. Alternatively, the ability of KLK6 to self-activate has also been reported, suggesting a positive feedback activation loop control mechanism. Activation of pro-KLK6 requires hydrolysis after a Lys residue; however, KLK6 exhibits 2 order of magnitude reduced affinity for hydrolysis after Lys versus Arg residues; therefore, the ability to autolytically activate has been called into question. In the present study the catalytic activity of KLK6 toward its pro-sequence and internal autolytic sequence is characterized. The results show that the ability of KLK6 to activate pro-KLK6 is essentially negligible when compared to the rate of the internal autolytic inactivation or to the ability of other proteases to activate pro-KLK6. The results thus show that the primary autolytic regulatory mechanism of KLK6 is negative feedback inhibition, and activation is likely achieved through the action of a separate protease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417874      PMCID: PMC2517904          DOI: 10.1021/bi6025006

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  44 in total

1.  Enzymatic properties of rat myelencephalon-specific protease.

Authors:  Sachiko I Blaber; Isobel A Scarisbrick; Matthew J Bernett; Pushparani Dhanarajan; Margaret A Seavy; Yonghao Jin; Martin A Schwartz; Moses Rodriguez; Michael Blaber
Journal:  Biochemistry       Date:  2002-01-29       Impact factor: 3.162

2.  Analysis of the human lumbar cerebrospinal fluid proteome.

Authors:  Xianglin Yuan; Tara Russell; George Wood; Dominic M Desiderio
Journal:  Electrophoresis       Date:  2002-04       Impact factor: 3.535

3.  Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.

Authors:  Matthew J Bernett; Sachiko I Blaber; Isobel A Scarisbrick; Pushparani Dhanarajan; Steven M Thompson; Michael Blaber
Journal:  J Biol Chem       Date:  2002-04-30       Impact factor: 5.157

4.  Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma.

Authors:  Eleftherios P Diamandis; Akira Okui; Shinichii Mitsui; Liu-Ying Luo; Antoninus Soosaipillai; Linda Grass; Terukazu Nakamura; David J C Howarth; Nozomi Yamaguchi
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

5.  Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.

Authors:  L Y Luo; D Katsaros; A Scorilas; S Fracchioli; R Piccinno; I A Rigault de la Longrais; D J Howarth; E P Diamandis
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

6.  The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family.

Authors:  F Xavier Gomis-Rüth; Alex Bayés; Georgia Sotiropoulou; Georgios Pampalakis; Theodoros Tsetsenis; Virtudes Villegas; Francesc X Avilés; Miquel Coll
Journal:  J Biol Chem       Date:  2002-05-16       Impact factor: 5.157

7.  Characterization of a brain-related serine protease, neurosin (human kaillikrein 6), in human cerebrospinal fluid.

Authors:  A Okui; K Kominami; H Uemura; S Mitsui; N Yamaguchi
Journal:  Neuroreport       Date:  2001-05-25       Impact factor: 1.837

8.  Activity of a newly identified serine protease in CNS demyelination.

Authors:  I A Scarisbrick; S I Blaber; C F Lucchinetti; C P Genain; M Blaber; M Rodriguez
Journal:  Brain       Date:  2002-06       Impact factor: 13.501

9.  The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.

Authors:  George M Yousef; Carl Kapadia; Mary-Ellen Polymeris; Carla Borgono; Shirley Hutchinson; Gregory A Wasney; Antoninus Soosaipillai; Eleftherios P Diamandis
Journal:  Biochim Biophys Acta       Date:  2003-07-28

10.  Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease.

Authors:  Sachiko I Blaber; Bogoljub Ciric; George P Christophi; Matthew J Bernett; Michael Blaber; Moses Rodriguez; Isobel A Scarisbrick
Journal:  FASEB J       Date:  2004-03-19       Impact factor: 5.191

View more
  13 in total

1.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

2.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

Review 3.  The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease.

Authors:  I A Scarisbrick
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

4.  Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases.

Authors:  Hyesook Yoon; Sachiko I Blaber; Wu Li; Isobel A Scarisbrick; Michael Blaber
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

Review 5.  Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Authors:  Michael Blaber; Hyesook Yoon; Maria A Juliano; Isobel A Scarisbrick; Sachiko I Blaber
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

6.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

7.  A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.

Authors:  Hyesook Yoon; Sachiko I Blaber; Mekdes Debela; Peter Goettig; Isobel A Scarisbrick; Michael Blaber
Journal:  Biol Chem       Date:  2009-04       Impact factor: 3.915

8.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

Review 9.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

10.  Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment.

Authors:  Stefanie Krenzer; Heike Peterziel; Cornelia Mauch; Sachiko I Blaber; Michael Blaber; Peter Angel; Jochen Hess
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.